Universitair Ziekenhuis Gent
Verified site
Gent, Belgium
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on two common viral infections, Influenza and COVID-19. Participants will receive an investigational mRNA Seasonal Flu/COVID-19 combination vaccine, which uses a small piece of genetic material (mRNA) to teach the body’s cells to produce a harmless part of the viruses so the immune system can learn to recognize them. For comparison, some participants may receive a standard flu shot, the COVID‑19 vaccine known as tozinameran, or the COVID‑19 vaccine called elasomeran. The vaccine is given as a single injection into the muscle.
The purpose of the study is to assess the safety and immune response of the vaccine. After the injection, blood samples are taken before vaccination and again about a month later to measure the level of protective proteins called antibodies, using a test called HI titers. Participants are asked to record any mild side effects such as soreness at the injection site, fever, or fatigue for the first week, and they are monitored for any health changes for up to six months. This schedule helps researchers understand how well the vaccine works and whether it is well tolerated.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
25 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Gent, Belgium
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an experimental vaccine being tested for the first time. It contains messenger RNA (mRNA) that tells the body’s cells to make parts of both the seasonal flu virus and the COVID‑19 virus. By showing these pieces to the immune system, the vaccine aims to teach the body to recognize and fight both illnesses if it encounters them later. In the study, the vaccine is given as a liquid that is injected into a muscle.
is a trivalent influenza vaccine that protects against three strains of the flu virus: two types of influenza A (H1N1 and H3N2) and one type of influenza B. The vaccine contains inactivated (killed) virus particles, so it cannot cause flu. It is given as an injection into the muscle to help the immune system develop antibodies that can prevent flu infection during the season.
is another trivalent influenza vaccine designed for the 2026/2027 flu season. Like Efluelda, it includes inactivated virus from two influenza A strains and one influenza B strain. The vaccine is administered by injection into the muscle and works by stimulating the body’s immune response so that it can recognize and fight the flu viruses that are expected to circulate that season.
is an mRNA COVID‑19 vaccine (the same technology used in some widely known COVID‑19 shots). The vaccine contains mRNA that instructs cells to produce a harmless piece of the SARS‑CoV‑2 spike protein, prompting the immune system to build protection against COVID‑19. It is given as a muscle injection.
is also an mRNA COVID‑19 vaccine. Similar to Tozinameran, it delivers mRNA that causes the body’s cells to make a small part of the coronavirus spike protein, training the immune system to recognize and fight the real virus. The vaccine is administered by injection into a muscle.
This vaccine is given as an intramuscular injection in a liquid form. It is still experimental and currently being studied in early‑phase clinical trials, so it is not yet approved for general use. It is designed to protect adults against both seasonal influenza and COVID‑19. The vaccine uses messenger RNA to tell body cells to produce pieces of flu and coronavirus proteins, which then train the immune system to recognize the real viruses. It belongs to the class of mRNA combination vaccines.
Efluelda is administered by intramuscular injection as a suspension. It is an approved, widely used seasonal flu vaccine that protects against influenza A (H1N1 and H3N2) and influenza B viruses. The vaccine contains killed (inactivated) virus particles that safely stimulate the body’s immune response. It is classified as an inactivated influenza vaccine.
Tozinameran is given as an intramuscular injection in a liquid form. It is an approved COVID‑19 vaccine (Pfizer‑BioNTech) that is used to prevent infection with the SARS‑CoV‑2 virus. The vaccine carries messenger RNA that directs cells to make the virus’s spike protein, prompting the immune system to build protection. It belongs to the class of mRNA vaccines.
Elasomeran is administered intramuscularly as a liquid injection. It is an approved COVID‑19 vaccine (Moderna) intended to prevent COVID‑19 disease. Like other mRNA vaccines, it delivers genetic instructions for the spike protein of SARS‑CoV‑2, which triggers an immune response. It is classified as an mRNA vaccine.
Influsplit is given by intramuscular injection as a suspension. It is an approved seasonal influenza vaccine for the 2026/2027 flu season, covering influenza A (H1N1 and H3N2) and influenza B strains. The product contains inactivated (killed) virus particles that safely activate the immune system to fight flu viruses. It falls under the category of inactivated influenza vaccines.
Influenza is an acute respiratory infection caused by influenza viruses that spreads through droplets when an infected person coughs or sneezes. Symptoms usually begin suddenly with fever, chills, cough, sore throat, muscle aches, and fatigue. The virus first multiplies in the upper airways and can then move into the lower respiratory tract. Peak symptoms typically occur 2 to 3 days after onset and then start to improve. Most people recover within about a week, although a lingering cough or tiredness may last longer.
COVID-19 is the disease caused by the SARS‑CoV‑2 virus, transmitted mainly by respiratory droplets and close contact. It often starts with fever, cough, loss of smell or taste, and mild fatigue. The virus initially infects cells in the nose and throat and can spread to the lungs, leading to increased respiratory symptoms. Over several days, symptoms may become more pronounced, with cough and shortness of breath developing as the infection progresses. Recovery usually occurs within a few weeks, although some people may experience lingering mild symptoms.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.